

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5950414

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BIOPHARMAWORKS LLC	04/24/2019
RECEIVING PARTY DATA		
Name:	LIXTE BIOTECHNOLOGY, INC.	
Street Address:	248 ROUTE 25A, NO. 2	
City:	EAST SETAUKET	
State/Country:	NEW YORK	
Postal Code:	11733	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16782970
CORRESPONDENCE DATA		
Fax Number:	(617)426-6567	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-728-7100	
Email:	BOSPatents@dechert.com	
Correspondent Name:	DECHERT LLP	
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR	
Address Line 2:	100 OLIVER STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02110-2605	
ATTORNEY DOCKET NUMBER:	395676-022USD1C2 (172166)	
NAME OF SUBMITTER:	TODD MACKLIN	
SIGNATURE:	/Todd Macklin/	
DATE SIGNED:	02/06/2020	
Total Attachments: 4		
source=Lixte_172166_Assignment_BioPharmaWorks-Lixte#page1.tif		
source=Lixte_172166_Assignment_BioPharmaWorks-Lixte#page2.tif		
source=Lixte_172166_Assignment_BioPharmaWorks-Lixte#page3.tif		
source=Lixte_172166_Assignment_BioPharmaWorks-Lixte#page4.tif		

CONFIRMATION OF ASSIGNMENT

WHEREAS, we, the undersigned, BIOPHARMAWORKS LLC, having a place of business at 93 Shennecossett Road, Groton, Connecticut 06340, USA (hereinafter termed "Assignor"), owner of an interest in the right, title and interest in and to certain new and useful improvements disclosed in "OXABICYCLOHEPTANE PRODRUGS," set forth in the applications and patent (hereinafter termed "application") listed in the attached Schedule A, and by virtue of a prior assignment from inventors Robert VOLKMANN and Anthony MARFAT (hereinafter termed "Inventors"), and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries;

WHEREAS, LINTE BIOTECHNOLOGY, INC., having a place of business at 248 Route 25A, No. 2, East Setauket, New York 11733, USA (hereinafter termed "Assignee"), is desirous of acquiring Assignor's entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey, and/or confirm prior sale, assignments, transfer, and conveyance, unto said Assignee, Assignor's entire right, title and interest: (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefore and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.

4. Said Assignor hereby warrants and represents that he has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignor.

Date: 4/27/2019

Assignor: BIOPHARMAWORKS LLC

Signed: Robert A. Volkman

Print Name: ROBERT A. VOLKMAN

Print Title: CSO

Address: 93 Shennecossett Road, Groton
Connecticut 06340, USA

Witness: [Signature]

Witness: [Signature]

Date: 25 April 2019

Assignee: LINTE BIOTECHNOLOGY, INC.

Signed: *John S. Kovach*

Print Name: John S Kovach

Print Title: President + CEO

Address: 248 Route 25A, No. 2, East Setauket
New York 11733, USA

Witness: *Robert C. H. Kovach*

Witness: _____

SCHEDULE A

- U.S. Patent Application No. 62/162,501, filing date of May 15, 2015;
- U.S. Patent Application No. 15/154,304, filing date of May 13, 2016, now U.S. Patent No. 9,988,394, issued June 5, 2018;
- U.S. Patent Application No. 15/968,462, filing date of May 1, 2018; and
- PCT International Patent Application No. PCT/US2016/032123, filing date of May 12, 2016